Edition:
India

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

54.73USD
22 Jul 2016
Change (% chg)

$0.10 (+0.18%)
Prev Close
$54.63
Open
$54.77
Day's High
$54.96
Day's Low
$54.35
Volume
610,996
Avg. Vol
1,155,421
52-wk High
$72.31
52-wk Low
$48.01

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $50,478.28
Shares Outstanding(Mil.): 914.07
Dividend: 0.34
Yield (%): 2.48

Financials

  TEVA.N Industry Sector
P/E (TTM): 28.49 36.47 37.34
EPS (TTM): 1.92 -- --
ROI: 4.98 14.88 14.14
ROE: 6.40 15.96 15.35

BRIEF-Fitch rates Teva Pharmaceutical's new EUR and CHF bonds 'BBB'

* Fitch rates Teva Pharmaceutical's new EUR and CHF bonds 'BBB' Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

23 Jul 2016

Fitch Rates Teva Pharmaceutical's New EUR and CHF Bonds 'BBB'

(The following statement was released by the rating agency) CHICAGO, July 22 (Fitch) Fitch Ratings has assigned 'BBB' ratings to the EUR4 billion and CHF1 billion of new bonds issued by finance subsidiaries of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; 'BBB'/Stable). Teva previously issued $15 billion of USD-denominated bonds on July 18, 2016. The approximately $20 billion of proceeds from the bond issuances, together with up to $5 billion of expected draws on committed term loan facil

23 Jul 2016

Investors scrap for Teva Pharmaceutical bonds

NEW YORK, July 22 (IFR) - Teva Pharmaceutical raised more than US$20bn across three currencies this week via an acquisition-driven bond that took advantage of pent-up demand for corporate paper in a yield-starved market.

22 Jul 2016

BRIEF-Teva announces pricing of additional CHF1.0 billion of senior notes

* Teva announces pricing of additional CHF1.0 billion of senior notes in connection with pending acquisition of actavis generics

22 Jul 2016

REFILE-Teva sets final price terms for SFr1bn bond deal

LONDON, July 21 (IFR) - Teva Pharmaceutical has set final price terms for a SFr1bn three-tranche bond issue to help fund its US$40.5bn acquisition of Actavis Generics, according to a lead bank.

21 Jul 2016

BRIEF-Fitch downgrades Teva Pharmaceuticals; rates new bonds 'BBB'

* Fitch downgrades Teva Pharmaceuticals; rates new bonds 'BBB'

20 Jul 2016

Your inhaler's watching you: drugmakers race for smart devices

LONDON, July 20 Makers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly.

20 Jul 2016

Teva sets final terms for expected 4bn M&A bond

LONDON, July 20 (IFR) - Teva Pharmaceutical has set final spreads for an expected 4bn multi-tranche issue to help fund its US$40.5bn acquisition of Actavis Generics, according to a lead bank.

20 Jul 2016

Teva sets guidance for three tranche euro-denominated M&A bond

LONDON, July 20 (IFR) - Teva Pharmaceutical has set guidance for a multi-tranche bond issue to help fund its US$40.5bn acquisition of Actavis Generics, according to a lead bank.

20 Jul 2016

Teva Pharm prices $15 bln in notes to fund Allergan generics deal

TEL AVIV, July 19 Teva Pharmaceutical Industries Ltd said on Tuesday it successfully priced a debt offering for $15 billion worth of senior notes to help fund its acquisition of Allergan Plc's generic drug business.

19 Jul 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF82.35 +0.40
Biogen Inc (BIIB.OQ) $287.78 +5.33

Earnings vs. Estimates